GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...
GSK’s GSK’227 has gained Priority Medicines (PRIME) designation from the EMA for the treatment of relapsed ES-SCLC.
GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in ...
The US Food and Drug Administration (FDA) has approved the first oral treatment for anaemia caused by chronic kidney disease (CKD) in adults on dialysis for at least four months: GlaxoSmithKline ...
GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of ...
It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.
T he US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab ...
The U.S. Food and Drug Administration has revoked the Emergency Use Authorization for bamlanivimab administered alone, bamlanivimab and ...
GSK had great expectations for Blenrep after its accelerated FDA approval in 2020 as a fourth-line or later treatment for multiple myeloma, which came crashing down with the failure of the DREAMM ...
Recent developments in health news include GSK's mixed results in cancer treatment trials, Novo Nordisk's market plunge ...
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...